📰 Data Expected News
Data Expected News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Data Expected. Real-time updates on events, politics, business and more.
May 3, 2024
Apple is rallying on an earnings beat and announcement of a massive buyback; U.S. jobs data are due; Amgen soars after providing an update on a weight loss drug; and Cloudflare plunges on a weak outlook. Here’s what investors need to know today.
January 16, 2024
Fed to Weigh Shrinking Its Balance Sheet at a Slower Pace; Weak Growth Forecast for U.S. This Year By James Christie Good day. By shrinking its holdings of bonds and other assets, the Federal...
December 20, 2023
Enrollment completed in placebo-controlled, randomized, dose-finding, multi-country, multi-center Phase II sepsis studyTopline Data Expected in late Q1 2024 Nes-Ziona, Israel, Dec. 20, 2023 ...
October 16, 2023
- Excellent Safety Profile, Stable Vision, and Reduced Frequency of Injections Observed for up to 6 months – - ODYSSEY Phase 2b Clinical Trial Enrollment is On Track with Data Expected in Q3...
October 16, 2023
- Excellent Safety Profile, Stable Vision, and Reduced Frequency of Injections Observed for up to 6 months – - ODYSSEY Phase 2b Clinical Trial...
June 2, 2023
The SCCS Notes of Guidance for the Testing of Cosmetic Ingredients and Their Safety Evaluation includes section on special consideration for certain cosmetic ingredients, including nanomaterials. It Defines nanomaterials, potential safety issues and requires safety data
June 2, 2023
The European Commission’s (EC) Scientific Committee on Consumer Safety (SCCS) published on May 16, 2023, the 12th revision of The SCCS Notes of Guidance for the Testing of Cosmetic...
May 10, 2023
TN-201 Received Fast Track Designation from the FDA Dosing Complete in Phase 1 Clinical Trial of TN-301; Data Expected in Second Half 2023 Renowned Researchers Drs. Christine Seidman and Alex Marson... | May 10, 2023
April 26, 2023
Conference call scheduled for 4:30 p.m. ET today Three Additional Data Announcements Expected in 2023Completed Enrollment in Phase 2b VOYAGE Study of VK2809 for NASH and Fibrosis; Data Expected in... | April 26, 2023
February 8, 2023
/PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...